Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.
Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, Müller F, Tovar N, Oliver-Cáldes A, Vucinic V, Kharboutli S, Bärmann BN, Ayuk F, Platzbecker U, Stölzel F, Schub N, Schmitz F, Fandrei D, Born P, Khandanpour C, Hanoun C, Hörster K, Teichert M, Jeker B, Hoffmann M, Kröger N, de Larrea CF, Pabst T, Gagelmann N. Merz M, et al. Among authors: fandrei d. Hemasphere. 2025 Jan 16;9(1):e70070. doi: 10.1002/hem3.70070. eCollection 2025 Jan. Hemasphere. 2025. PMID: 39822585 Free PMC article.
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TAW, Fenk R, Müller F, Tovar N, Oliver-Cáldes A, Rathje K, Davis JA, Fandrei D, Vucinic V, Kharboutli S, Baermann BN, Ayuk F, Platzbecker U, Albici AM, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kröger N, von Tresckow B, de Larrea CF, Pabst T, Abdallah AO, Gagelmann N. Merz M, et al. Among authors: fandrei d. Blood Cancer J. 2024 Dec 5;14(1):214. doi: 10.1038/s41408-024-01197-2. Blood Cancer J. 2024. PMID: 39632797 Free PMC article.
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.
Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P, Wiemers T, Weidner H, Kreuz M, Schassberger T, Koßmann J, Mangold M, Fürst D, Fischer L, Baber R, Heyn S, Wang SY, Bach E, Hoffmann S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Köhl U, Friedrich M, Boldt A, Reiche K, Platzbecker U, Vucinic V, Merz M. Fandrei D, et al. Blood Cancer Discov. 2025 Jan 8;6(1):38-54. doi: 10.1158/2643-3230.BCD-24-0118. Blood Cancer Discov. 2025. PMID: 39441177